1Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, Massachusetts.
2Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts.
Hum Gene Ther. 2019 Aug;30(8):946-956. doi: 10.1089/hum.2018.253. Epub 2019 Jun 17.
Recombinant adeno-associated viruses (rAAVs) have become favorable gene delivery vehicles for expressing therapeutic transgenes. Capsid engineering efforts to produce novel AAVs with improved transduction efficiencies, unique tissue specificities, and reduced host immunities are a direct response to the high demand for treatment needs that preexisting rAAVs cannot currently fulfill. New AAV capsids discovered by directed evolution methods, design, or from natural proviral sequences ultimately require extensive characterization in relevant models. Consequently, quantitative screening of candidate capsid libraries now requires reliable high-throughput sequencing approaches. In this study, we have developed a vector/transgene tracking system that employs the indexing of a non-coding RNA. Specifically, a barcoded Tough Decoy () that express highly stable RNA transcripts that can be used as readouts for transduction efficiency. The pseudo-hairpin structure of the contains a variable region that is amenable to barcode insertion, which can be detected by target amplicon sequencing. The described approach, named AAV- screening, offers a new alternative for assessment of rAAV that can accurately quantify vector genomes and transcript abundances in tissues, as exampled by the demonstration in liver and brain infections. Proof-of-concept is provided to show that vector genome and transcript detection in tissues with this method is accurate and consistent for a vector dose range of upwards to four logs in a mixed vector injection, showing that this technique is robust, sensitive, and applicable for multiplexed screening of capsid performance .
重组腺相关病毒 (rAAV) 已成为表达治疗性转基因的理想基因传递载体。为了生产具有改进转导效率、独特组织特异性和降低宿主免疫原性的新型 AAV,人们进行了衣壳工程改造,这是对现有 rAAV 目前无法满足的高治疗需求的直接回应。通过定向进化方法、设计或天然前病毒序列发现的新型 AAV 衣壳,最终需要在相关模型中进行广泛的表征。因此,候选衣壳文库的定量筛选现在需要可靠的高通量测序方法。在这项研究中,我们开发了一种载体/转基因追踪系统,该系统采用非编码 RNA 的索引。具体来说,是一种带有条形码的 Tough Decoy(TD),它表达高度稳定的 RNA 转录本,可以作为转导效率的读出值。TD 的伪发夹结构包含一个可插入条形码的可变区,可以通过靶标扩增子测序进行检测。该方法被命名为 AAV 筛选,为 rAAV 的评估提供了一种新的替代方法,可以准确量化组织中的载体基因组和转录本丰度,如在肝脏和大脑感染中的演示所示。提供了概念验证,表明使用该方法在组织中检测载体基因组和转录本是准确且一致的,对于混合载体注射中高达四个对数的载体剂量范围,表明该技术具有稳健性、敏感性和适用于衣壳性能的多路复用筛选。